187 related articles for article (PubMed ID: 32021902)
1. Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries.
Olimpieri PP; Di Lenarda A; Mammarella F; Gozzo L; Cirilli A; Cuomo M; Gulizia MM; Colivicchi F; Murri G; Gabrielli D; Trotta F
Int J Cardiol Heart Vasc; 2020 Feb; 26():100465. PubMed ID: 32021902
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
4. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
[TBL] [Abstract][Full Text] [Related]
5. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
[TBL] [Abstract][Full Text] [Related]
6. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
7. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
Fosbøl EL; Vinding NE; Lamberts M; Staerk L; Gundlund A; Gadsbøll K; Køber L; Gislason GH; Olesen JB
Europace; 2018 Jun; 20(6):e78-e86. PubMed ID: 28666358
[TBL] [Abstract][Full Text] [Related]
8. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
9. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
10. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
[No Abstract] [Full Text] [Related]
11. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
Staerk L; Fosbøl EL; Lip GYH; Lamberts M; Bonde AN; Torp-Pedersen C; Ozenne B; Gerds TA; Gislason GH; Olesen JB
Eur Heart J; 2017 Mar; 38(12):907-915. PubMed ID: 27742807
[TBL] [Abstract][Full Text] [Related]
12. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
Brown JD; Shewale AR; Talbert JC
J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
14. Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation.
Gozzo L; Di Lenarda A; Mammarella F; Olimpieri PP; Cirilli A; Cuomo M; Gulizia MM; Colivicchi F; Murri G; Kunutsor SK; Gabrielli D; Trotta F
Sci Rep; 2021 Oct; 11(1):20689. PubMed ID: 34667256
[TBL] [Abstract][Full Text] [Related]
15. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Hohnloser SH; Basic E; Nabauer M
Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of a prospective, multicenter, cross-sectional study of appropriateness evaluation of the prescription of non-vitamin K antagonist oral anticoagulants for Chinese atrial fibrillation patients (Chi-NOACs-AF trial).
Ding Z; Zhang C; Qian YY; Wang N; Gu ZC; Xu H; Zheng YL
Ann Transl Med; 2021 Apr; 9(7):580. PubMed ID: 33987278
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
19. Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation.
Park S; Je NK
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):656-664. PubMed ID: 34558337
[TBL] [Abstract][Full Text] [Related]
20. [Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?].
Bahrmann P; Christ M
Herz; 2018 May; 43(3):214-221. PubMed ID: 29260237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
